Jeffrey H. Chen

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Matthew R. Janes, Jingchuan Zhang, Lian‐Sheng Li et al. · Cell · 2018 · 1.1K citations · Full text

Kras Mutant Cancers, Medicine, Anti-cancer Agent +6

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

Matthew P. Patricelli, Matthew R. Janes, Lian‐Sheng Li et al. · Cancer Discovery · 2016 · 731 citations · Full text

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

Dana D. Hu‐Lowe, Helen Y. Zou, Maren L. Grazzini et al. · Clinical Cancer Research · 2008 · 620 citations

Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

Michele McTigue, Brion W. Murray, Jeffrey H. Chen et al. · Proceedings of the National Academy of Sciences · 2012 · 538 citations · Full text

Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies

Dana D. Hu‐Lowe, Enhong Chen, Lianglin Zhang et al. · Cancer Research · 2011 · 132 citations · Full text

Action Complementary, Immunology, Tumor Biology +16